Program
sitagliptin
Also written as “Sitagliptin”, “sitagliptin phosphate” and “Sitagliptin phosphate”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Glucose Intolerance · Renal Insufficiency · Hepatic Insufficiency, led by 11 companies.
Drug pageSitagliptin: every studyMany companies study it; this page follows only the 101 they lead. All 306 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 780 open or running | phase 4since Jan 28, 2009 | Jul 2, 2004 | none ahead |
| Ono Pharmaceuticalits history only | 50 open or running | phase 3since Aug 11, 2006 | Aug 11, 2006 | none ahead |
| ADIUMits history only | 40 open or running | no phasesince Aug 10, 2026 | Aug 10, 2026 | none ahead |
| Novo Nordiskits history only | 40 open or running | phase 4since Jan 24, 2012 | Jun 18, 2008 | none ahead |
| Bio-innovaits history only | 22 open or running | phase 1since Dec 15, 2023 | Dec 15, 2023 | none ahead |
| Novartisits history only | 20 open or running | phase 4since Sep 13, 2012 | Jun 12, 2012 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 20 open or running | phase 2since Aug 28, 2013 | Aug 28, 2013 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 1since Jun 30, 2016 | Jun 30, 2016 | none ahead |
| Dong Wha Pharmaceuticalits history only | 10 open or running | phase 1since May 4, 2022 | May 4, 2022 | none ahead |
| Getz Pharmaits history only | 10 open or running | phase 4since Nov 29, 2021 | Nov 29, 2021 | none ahead |
| KineMedits history only | 10 open or running | no phasesince Mar 23, 2010 | Mar 23, 2010 | none ahead |
Also a collaborator on its studies: Parexel, Pfizer, Bristol-Myers Squibb and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 42 studies since Aug 6, 2008.
- Jan 2, 2013Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT01760447 · 223 enrolled
- Jul 22, 2013Phase 4 study in Diabetes MellitusNovo Nordisk · NCT01907854 · 407 enrolled · United States, Canada, Hungary and more
- Aug 28, 2013Profil Institut für Stoffwechselforschung’s first study: phase 2 study in Diabetes Mellitus, Type 2New to Profil Institut für StoffwechselforschungProfil Institut für Stoffwechselforschung · NCT01936025 · 34 enrolled · Germany
- Mar 25, 2014Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02099110 · 1,233 enrolled
- Dec 12, 2014Phase 4 study in Diabetes Mellitus, Type 2Merck · NCT02318693 · 53 enrolled
- Aug 25, 2015Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02532855 · 614 enrolled
- Apr 11, 2016Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02738879 · 746 enrolled
- Jun 1, 2016Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02791490 · 458 enrolled
- Jun 30, 2016Chong Kun Dang Pharmaceutical’s first study: phase 1 study in Diabetes Mellitus, Type 2New to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT02827890 · 20 enrolled · Korea, Republic of
- Nov 24, 2017Phase 2 study in Pharmacological ActionProfil Institut für Stoffwechselforschung · NCT03359590 · 20 enrolled · Germany
- Nov 29, 2021Getz Pharma’s first study: phase 4 study in Diabetes Mellitus, Type 2New to Getz PharmaGetz Pharma · NCT05167513 · 188 enrolled · Pakistan
- May 4, 2022Dong Wha Pharmaceutical’s first study: phase 1 study in Healthy SubjectsNew to Dong Wha PharmaceuticalDong Wha Pharmaceutical · NCT05403281 · 41 enrolled · Korea, Republic of
- Jul 21, 2022Named sitagliptinINNProposed as its International Nonproprietary Name in WHO's List 127
- Dec 15, 2023Bio-innova’s first studies: 2 phase 1 studies in Healthy SubjectsNew to Bio-innovaBio-innova · NCT06233240, NCT06233201
- Aug 10, 2026ADIUM’s first studies: 4 no phase studiesNew to ADIUMADIUM · NCT07763964, NCT07763951, NCT07763912 and 1 more
TargetBeta
“Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Linagliptinrule | Boehringer Ingelheim | phase 4 | 96 |
| gemigliptinrule | LG Chem | phase 4 | 30 |
| anagliptinrule | JW Pharmaceutical | phase 4 | 6 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 1 |
Studies
The newest 60 of 101 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07763964Bioequivalance · Mexico | – | Completed | ADIUM | Dec 19, 2025 | 46 |
| NCT07763951Bioequivalance · Mexico | – | Completed | ADIUM | Dec 14, 2025 | 46 |
| NCT07763912Bioequivalence · Mexico | – | Completed | ADIUM | Dec 5, 2025 | 46 |
| NCT07763899Bioequivalance · Mexico | – | Completed | ADIUM | Nov 30, 2025 | 46 |
| NCT06233240Healthy Subjects | 1 | Not yet recruiting | Bio-innova | May 29, 2024 | 34 |
| NCT06233201Healthy Subjects | 1 | Not yet recruiting | Bio-innova | Jul 14, 2024 | 34 |
| NCT05403281Healthy Subjects · Korea, Republic of | 1 | Completed | Dong Wha Pharmaceutical | Dec 3, 2021 | 41 |
| NCT05167513Diabetes Mellitus, Type 2 · Pakistan | 4 | Completed | Getz Pharma | Apr 28, 2022 | 188 |
| NCT03359590Pharmacological Action · Germany | 2 | Completed | Profil Institut für Stoffwechselforschung | Jul 17, 2019 | 20 |
| NCT02827890Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Apr 2016 | 20 |
| NCT02791490Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Feb 1, 2018 | 458 |
| NCT02738879Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jan 22, 2018 | 746 |
| NCT02532855Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Oct 10, 2017 | 614 |
| NCT02318693Diabetes Mellitus, Type 2 | 4 | Completed | Merck | Dec 15, 2015 | 53 |
| NCT02099110Diabetes Mellitus, Type 2 | 3 | Completed | Merck | May 26, 2016 | 1,233 |
| NCT01936025Diabetes Mellitus, Type 2 · Germany | 2 | Completed | Profil Institut für Stoffwechselforschung | Apr 2014 | 34 |
| NCT01907854Diabetes Mellitus · United States, Canada, Hungary and more | 4 | Completed | Novo Nordisk | Jun 15, 2015 | 407 |
| NCT01760447Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Sep 17, 2019 | 223 |
| NCT01702298Diabetes Mellitus, Type 2 | 3 | Completed | Merck | May 29, 2013 | 42 |
| NCT01686932Diabetes Mellitus, Type 2 · Germany | 4 | Completed | Novartis | Sep 2014 | 51 |
| NCT01678820Diabetes Mellitus, Type 2 | 3 | Terminated | Merck | Nov 1, 2013 | 299 |
| NCT01619332Diabetes Mellitus, Type 2 · United States | 2 | Completed | Novartis | Sep 2013 | 220 |
| NCT01590797Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jun 11, 2014 | 467 |
| NCT01590771Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jun 10, 2014 | 498 |
| NCT01582308Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Dec 4, 2012 | 22 |
| NCT01557504Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Apr 29, 2014 | 25 |
| NCT01519674Diabetes Mellitus · Argentina, Australia, Brazil and more | 4 | Completed | Novo Nordisk | Oct 2013 | 582 |
| NCT01485614Diabetes Mellitus | 3 | Completed | Merck | Oct 9, 2019 | 200 |
| NCT01477853Diabetes Mellitus, Type 2 | 3 | Terminated | Merck | Dec 4, 2012 | 166 |
| NCT01517321Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Ono Pharmaceutical | ||
| NCT01462266Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jun 6, 2013 | 660 |
| NCT01405911Glucose Intolerance | 2 | Completed | Merck | Apr 9, 2012 | 242 |
| NCT01340768Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Sep 21, 2011 | 870 |
| NCT01296412Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Feb 29, 2012 | 653 |
| NCT01189890Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Oct 31, 2012 | 480 |
| NCT01177384Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Mar 25, 2013 | 380 |
| NCT01131182Diabetes Mellitus, Type 2 | 4 | Completed | Merck | Nov 4, 2010 | 1,147 |
| NCT01092663Diabetes Mellitus, Type 2 · United States | – | Completed | KineMed | Jul 2011 | 61 |
| NCT01093794Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Jun 2010 | 28 |
| NCT01076088Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Dec 24, 2012 | 744 |
| NCT01076075Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jul 11, 2011 | 427 |
| NCT01046110Diabetes Mellitus · United States, Argentina, Canada and more | 3 | Completed | Novo Nordisk | Nov 2010 | 458 |
| NCT01034111Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Oct 4, 2010 | 30 |
| NCT01028391Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jan 1, 2009 | 317 |
| NCT00993187Diabetes Mellitus, Type 2 | 4 | Completed | Merck | Oct 29, 2013 | 292 |
| NCT00975052Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Mar 2006 | 16 |
| NCT00944450Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Sep 2004 | 12 |
| NCT00929201Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Mar 2008 | 61 |
| NCT00888238Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Jun 10, 2009 | 12 |
| NCT00885352Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Nov 10, 2010 | 313 |
| NCT00875394Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Jun 27, 2008 | 68 |
| NCT00854035Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Ono Pharmaceutical | Jun 2010 | 266 |
| NCT00833027Diabetes Mellitus | 4 | Completed | Merck | Oct 30, 2009 | 608 |
| NCT00832624Diabetes Mellitus, Type 2 | 4 | Terminated | Merck | Sep 2, 2009 | 10 |
| NCT00832390Diabetes Mellitus | 4 | Completed | Merck | Jul 11, 2008 | 29 |
| NCT00830076Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Apr 30, 2009 | 18 |
| NCT00813995Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Aug 9, 2010 | 395 |
| NCT00790205Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Mar 30, 2015 | 14,671 |
| NCT00758069Diabetes Mellitus, Type 2 | 2 | Completed | Merck | Feb 13, 2006 | 80 |
| NCT00730275Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Dec 30, 2010 | 35 |
How it is read
Names in the registry
- “Sitagliptin”, 33 entries
- “sitagliptin phosphate”, 18 entries
- “sitagliptin”, 15 entries
- “Sitagliptin phosphate”, 10 entries
- “Sitagliptin/Metformin FDC”, 5 entries
Codes read as this program: MK0431.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 106 studies
- Diabetes Mellitus, 2 studies
- Glucose Intolerance, 1 study
- Renal Insufficiency, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.